Xuanming Teng, Jingyi Yang, Zhiyi Ren, Sha Yan, Jiaxin Zhai, Xinyuan Hu, Shule Hou, Yangyang Yang
{"title":"通过DNA模块化配体的程序化靶向蛋白质降解。","authors":"Xuanming Teng, Jingyi Yang, Zhiyi Ren, Sha Yan, Jiaxin Zhai, Xinyuan Hu, Shule Hou, Yangyang Yang","doi":"10.1002/cmdc.202500340","DOIUrl":null,"url":null,"abstract":"<p><p>Proteolysis targeting chimera (PROTAC) technology holds great promise as a protein degradation modality in therapeutic development. However, there remain challenges, including complex chemical synthesis and linker screening. To address this, a proof-of-concept of a new modularized method by constructing DNA-PROTAC is presented by identifying the valid BRD4 and Sirt2 DNA-PROTACs. These findings may provide new approaches for linker design and ligand screening for PROTACs. Herein, a ligand modularization strategy is proposed that leverages the programmability of DNA to modulate the design and construction of PROTAC molecules to facilitate the programmatic discovery of new PROTAC molecules. The bromodomain-containing protein 4 (BRD4) is selected as a target for degradation to verify the effectiveness of DNA-PROTACs. The kinetics of BRD4 degradation were assessed by performing time-course experiments in HeLa cells. In addition, to evaluate the feasibility of the DNA-PROTAC strategy for degradation of other proteins, the silent mating type information regulation 2 homolog-2 (Sirt2) is selected as the degradation target. The design and synthesis procedures of BRD4 and Sirt2 DNA-PROTACs and their mechanisms of action, are systematically introduced, and the results may provide a new method for linker design and ligand screening of PROTACs.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500340"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Programmed Targeted Protein Degradation Via DNA Modularized Ligand.\",\"authors\":\"Xuanming Teng, Jingyi Yang, Zhiyi Ren, Sha Yan, Jiaxin Zhai, Xinyuan Hu, Shule Hou, Yangyang Yang\",\"doi\":\"10.1002/cmdc.202500340\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Proteolysis targeting chimera (PROTAC) technology holds great promise as a protein degradation modality in therapeutic development. However, there remain challenges, including complex chemical synthesis and linker screening. To address this, a proof-of-concept of a new modularized method by constructing DNA-PROTAC is presented by identifying the valid BRD4 and Sirt2 DNA-PROTACs. These findings may provide new approaches for linker design and ligand screening for PROTACs. Herein, a ligand modularization strategy is proposed that leverages the programmability of DNA to modulate the design and construction of PROTAC molecules to facilitate the programmatic discovery of new PROTAC molecules. The bromodomain-containing protein 4 (BRD4) is selected as a target for degradation to verify the effectiveness of DNA-PROTACs. The kinetics of BRD4 degradation were assessed by performing time-course experiments in HeLa cells. In addition, to evaluate the feasibility of the DNA-PROTAC strategy for degradation of other proteins, the silent mating type information regulation 2 homolog-2 (Sirt2) is selected as the degradation target. The design and synthesis procedures of BRD4 and Sirt2 DNA-PROTACs and their mechanisms of action, are systematically introduced, and the results may provide a new method for linker design and ligand screening of PROTACs.</p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\" \",\"pages\":\"e202500340\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cmdc.202500340\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500340","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Programmed Targeted Protein Degradation Via DNA Modularized Ligand.
Proteolysis targeting chimera (PROTAC) technology holds great promise as a protein degradation modality in therapeutic development. However, there remain challenges, including complex chemical synthesis and linker screening. To address this, a proof-of-concept of a new modularized method by constructing DNA-PROTAC is presented by identifying the valid BRD4 and Sirt2 DNA-PROTACs. These findings may provide new approaches for linker design and ligand screening for PROTACs. Herein, a ligand modularization strategy is proposed that leverages the programmability of DNA to modulate the design and construction of PROTAC molecules to facilitate the programmatic discovery of new PROTAC molecules. The bromodomain-containing protein 4 (BRD4) is selected as a target for degradation to verify the effectiveness of DNA-PROTACs. The kinetics of BRD4 degradation were assessed by performing time-course experiments in HeLa cells. In addition, to evaluate the feasibility of the DNA-PROTAC strategy for degradation of other proteins, the silent mating type information regulation 2 homolog-2 (Sirt2) is selected as the degradation target. The design and synthesis procedures of BRD4 and Sirt2 DNA-PROTACs and their mechanisms of action, are systematically introduced, and the results may provide a new method for linker design and ligand screening of PROTACs.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.